- Home
- KZR vs VYNE Comparison
KZR vs VYNE Comparison
Compare KZR & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- VYNE
- Stock Information
- Founded
- KZR 2015
- VYNE 2003
- Country
- KZR United States
- VYNE United States
- Employees
- KZR N/A
- VYNE N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- VYNE Health Care
- Exchange
- KZR Nasdaq
- VYNE Nasdaq
- Market Cap
- KZR 43.0M
- VYNE 35.7M
- IPO Year
- KZR 2018
- VYNE 2018
- Fundamental
- Price
- KZR $6.05
- VYNE $2.74
- Analyst Decision
- KZR Hold
- VYNE Strong Buy
- Analyst Count
- KZR 2
- VYNE 2
- Target Price
- KZR $9.00
- VYNE $6.88
- AVG Volume (30 Days)
- KZR 26.2K
- VYNE 86.1K
- Earning Date
- KZR 03-13-2025
- VYNE 03-07-2025
- Dividend Yield
- KZR N/A
- VYNE N/A
- EPS Growth
- KZR N/A
- VYNE N/A
- EPS
- KZR N/A
- VYNE N/A
- Revenue
- KZR N/A
- VYNE $493,000.00
- Revenue This Year
- KZR N/A
- VYNE $28.30
- Revenue Next Year
- KZR N/A
- VYNE N/A
- P/E Ratio
- KZR N/A
- VYNE N/A
- Revenue Growth
- KZR N/A
- VYNE 39.27
- 52 Week Low
- KZR $5.20
- VYNE $1.57
- 52 Week High
- KZR $11.40
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- KZR 43.79
- VYNE 56.12
- Support Level
- KZR $5.86
- VYNE $2.39
- Resistance Level
- KZR $6.57
- VYNE $2.65
- Average True Range (ATR)
- KZR 0.27
- VYNE 0.20
- MACD
- KZR 0.02
- VYNE 0.05
- Stochastic Oscillator
- KZR 25.97
- VYNE 71.01
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.